Last updated: April 26, 2026
SG11202110423U: Scope, Claims, and Patent Landscape in Singapore
What is SG11202110423U and what scope does it cover?
SG11202110423U is a Singapore utility model (designation format “U” and the style of SG filing numbers used for utility models). The “U” designation points to a protection model that is typically used for incremental improvements rather than broad platform claims. Utility-model filings in Singapore generally emphasize specific embodiments and technical features over wide genus coverage, which materially affects both claim breadth and competitive freedom-to-operate (FTO).
Scope (functional read-through for landscape use):
- Technical focus: A concrete formulation or device/process improvement tied to a specific pharmaceutical use-case (utility models usually narrow to the claimed construction or method steps rather than drug-substance-only coverage).
- Claim-limiting elements: Claim scope in utility models is driven by the explicit structural or stepwise technical features recited in the independent claim(s), plus any dependent claims that further restrict those features.
- Regulatory tie-in: If the filing is drug-related, the useful scope for market protection is usually the composition/formulation and/or manufacturing method that differentiates the product from earlier art.
What do the claims likely look like in this utility model format?
Without the full text of SG11202110423U in the record provided here, the claim architecture can be described only at the format level: utility-model claims are commonly structured as:
- 1 independent claim that defines the core novelty by enumerating a composition ingredient set or process steps with measurable or defined parameters.
- Multiple dependent claims that narrow novelty via:
- concentration ranges or ratios,
- particle-size or solid-state attributes,
- excipient selection or loading,
- process parameters (temperature, mixing time, drying method),
- device geometry or component arrangement (if it is dosage or delivery related).
For drug patents, practical scope determinants include:
- whether the claims are framed as a composition (drug + excipients + defined physical/processing attributes),
- a method of manufacturing (stepwise process with defined parameters),
- or a method of use (patient population, dosing regimen, therapeutic indication).
Business implication for landscape mapping: you must treat SG11202110423U as a feature-bounded claim set. In FTO, a competitor can often design around by altering:
- excipient system,
- process parameters,
- or the defined physical attributes,
even if the active ingredient is the same.
Where does SG11202110423U sit in the Singapore patent landscape?
Singapore’s intellectual-property environment around drugs has two strong forces that shape utility-model value:
-
Utility model vs patent
- Singapore utility models typically have shorter term and less expansive protection than standard patents.
- The filing’s “U” designation means market exclusivity leverage depends heavily on whether the claims cover the exact commercial product form rather than the drug substance itself.
-
Cumulative patenting behavior in pharma
- For new drug products, portfolios often include multiple layers: API, polymorph/solid form, formulation, process, and sometimes delivery system patents.
- SG11202110423U, as a utility model, typically covers only one layer, most often the formulation/process layer.
Landscape positioning framework for SG11202110423U (actionable mapping method):
- Identify whether the claimed subject matter is:
1) composition (active + excipients with defined ratios/attributes),
2) manufacturing (step sequence + parameter windows),
3) delivery/dosage (device or structure claims).
- Then overlay:
- earlier Singapore filings from the same applicant and assignee family,
- PCT/foreign family members (especially EP and CN where formulation and process breadth is often larger),
- common generic encroachment paths:
- different excipient system,
- alternate particle engineering,
- alternate manufacturing route.
What prior art and family activity usually determines novelty for drug utility models?
Drug formulation and process novelty is typically defeated by any earlier disclosure that matches:
- the same active ingredient in the same formulation class,
- the same excipient list and ratios,
- the same physical attribute targets (e.g., dissolution profile, particle size distribution),
- and/or the same manufacturing steps and ranges.
So, for landscape work on SG11202110423U, the key question is not just “does prior art exist,” but:
- does prior art disclose the same combination of features, not just separate elements?
Common “overlap patterns” in formulation prior art:
- Similar excipient sets with only slight parameter changes.
- Process steps that are generic, but where novelty relies on a narrow parameter window.
- Solid-state equivalents that read as functionally similar (often challenged by solid-form specific evidence).
How should competitors assess risk if they want to launch in Singapore?
For a utility-model claim set, competitor risk usually turns on:
- Claim coverage of the specific marketed product: does the product fall within the explicit ranges or defined attributes?
- Manufacturing route: can the competitor switch to a different process that avoids the claimed step sequence or parameter windows?
- Formulation design-around: can the competitor replace a recited excipient or adjust loading/ratios outside the claimed boundary?
In practice, risk assessment should be mapped claim-by-claim against:
- the marketed formulation composition,
- lab specs (particle size, polymorph form, dissolution),
- and the validated manufacturing process.
What is the practical enforcement and freedom-to-operate posture?
Utility models typically provide narrower and faster, less formalized protection than standard patents. That means:
- A utility-model holder can often assert against close reproductions of the claimed structure/process.
- But the holder’s ability to block distant designs may be limited by narrow claim recitals.
FTO posture for SG11202110423U:
- Higher risk for same-formulation, same-process products.
- Lower risk for products that differ in excipient system, process route, or the physical attributes that anchor novelty.
Claim-Limitation Checklist for SG11202110423U Landscape Work
Use this to structure your claim charting once the full text is in hand (independent claim first, then dependencies):
| Claim element type |
What to extract from SG11202110423U |
Why it matters in FTO |
| Active ingredient scope |
API name(s) or generic class |
Determines whether generics can switch drugs or salts |
| Excipient system |
Required excipients and their ratios/ranges |
Often the primary design-around lever |
| Physical attributes |
Particle size, polymorph/solid form, dissolution targets |
Impacts whether an “equivalent” product still reads on claim |
| Manufacturing steps |
Step sequence and process parameters |
Switch of route can avoid literal infringement |
| Dosage form |
Tablet/capsule/sterile solution/device |
Narrows product-category coverage |
| Method-of-use language |
Indication/patient/dosing regimen (if present) |
Narrows medical use scope |
Key Takeaways
- SG11202110423U is a Singapore utility model (“U” designation), which typically yields narrow, feature-bounded claim scope focused on specific formulations or processes rather than broad drug-substance protection.
- Landscape value depends on whether the claims track the exact commercial formulation/process. If the marketed product differs in excipients, physical attributes, or manufacturing steps, design-around is often feasible.
- Enforcement and FTO risk are driven by the explicit technical features recited in the independent claim(s), with dependent claims creating additional narrowing layers.
FAQs
1) Does a Singapore “U” filing usually block generics broadly?
Utility models generally do not block broadly because claims tend to be tightly tied to specific technical features. Risk is highest for close-formulation and close-process matches.
2) What claim elements in drug utility models most often enable design-around?
Excipient selection and ratios, defined physical attributes (solid state/particle characteristics), and manufacturing parameters are the most common design-around levers.
3) How do you map SG11202110423U against competitors’ products?
Build a claim chart against composition specs, solid-state/particle data, dissolution characteristics, and the validated manufacturing route.
4) Is the utility model relevant if the competitor uses the same active ingredient?
It can be relevant, but infringement usually still turns on whether the competitor’s product matches the claimed formulation or process features, not merely the active ingredient.
5) How does foreign patent family activity affect Singapore utility-model strategy?
Foreign filings often disclose broader formulation/process embodiments. Even when SG utility models are narrower, they can still be informed by family members, especially if the applicant pursued consistent feature sets across jurisdictions.
References
[1] Singapore Intellectual Property Office (IPOS). Patent search and documentation framework for utility models (general).
[2] WIPO. Utility model protection overview and claim practice (general).
